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Abstract
We showed that IgA induces IL-10 in monocytes and dendritic cells. Because
reciprocal inhibition exists between IL-10 and IL-12, we explored whether IgA
could regulate this other immunoregulatory cytokine. In human monocytes and
monocyte-derived dendritic cells preincubated with IFN-γ before stimulation by
LPS, suppression of p40 and IL-12p70 production was observed upon IgA
treatment during IFN-γ priming. Washout experiments and inhibition of IFN-
γ-induced CXCL10 (IP-10) and FcgRI (CD64) indicated that inhibition by IgA
occurred at both the LPS and IFN-γ levels. Inhibition was not affected by
blockade of IL-10 or MAPK but involved FcaRI/CD89-mediated suppression
of STAT1 phosphorylation. These data indicate that FcaRI ligation on human
monocytes and dendritic cells inhibits IL-12 expression and type 1 activation by
interfering with STAT1 activation. Copyright © 2013 by The American Association
of Immunologists, Inc. All rights reserved.
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The Journal of Immunology
FcaRI-Mediated Inhibition of IL-12 Production and Priming
by IFN-g of Human Monocytes and Dendritic Cells
Maryle`ne Lecocq,* Bruno Detry,* Ame´lie Guisset,* and Charles Pilette*,†
We showed that IgA induces IL-10 in monocytes and dendritic cells. Because reciprocal inhibition exists between IL-10 and IL-12,
we explored whether IgA could regulate this other immunoregulatory cytokine. In human monocytes and monocyte-derived
dendritic cells preincubated with IFN-g before stimulation by LPS, suppression of p40 and IL-12p70 production was observed
upon IgA treatment during IFN-g priming. Washout experiments and inhibition of IFN-g–induced CXCL10 (IP-10) and FcgRI
(CD64) indicated that inhibition by IgA occurred at both the LPS and IFN-g levels. Inhibition was not affected by blockade of IL-10
or MAPK but involved FcaRI/CD89-mediated suppression of STAT1 phosphorylation. These data indicate that FcaRI ligation on
human monocytes and dendritic cells inhibits IL-12 expression and type 1 activation by interfering with STAT1 activation. The
Journal of Immunology, 2013, 190: 2362–2371.
A
ntigen presenting cells, including dendritic cells (DCs),
are master regulators of immune responses through their
unique capacity to both recognize danger signals and
subsequently activate T cells. The latter follows cognate interactions
between APCs and TCRs (signals 1 and 2), as well as secretion of
immunoregulatory cytokines (signal 3) that imprint the polarization
of the T cell response. In particular, APC-derived IL-12 represents
the major signal for T cells to differentiate into Th1 cells that
produce IFN-g. IL-12 can also trigger T cells to express TNF-a,
IL-2, IL-3, and GM-CSF (1), and it elicits the generation of CD8+
T cells and activated NK cells expressing cytotoxic effector mol-
ecules (e.g., perforin and granzymes). In addition, IL-12, along with
IFN-g, antagonizes Th2 differentiation.
IL-12p40 is secreted as monomers and homodimers in large
excess over IL-12p70 (the bioactive form of IL-12) both in vitro
and in vivo (2, 3). The p40 gene is highly inducible by microbial
products, and its promoter contains sites for NF-kB (4, 5), AP-1
(5), IRF-1 (6), and Ets family members (7, 8). Unlike p40, p35 is
regulated both transcriptionally and posttranscriptionally and, de-
spite constitutive p35 mRNA synthesis, little or no protein is se-
creted because of the presence of an inhibitory ATG motif in the
59-untranslated region (1, 9).
IFN-g is located both up- and downstream of IL-12, enhancing
IL-12 production while concomitantly suppressing IL-10 in re-
sponse to TLR stimulation (10). IFN-g produced by activated NK
cells or CD8+ T cells can skew the development of DCs toward
a type 1 phenotype with high IL-12 expression (11). In human
monocytes, production of bioactive IL-12 (p70) requires a com-
bination of stimuli, such as LPS and IFN-g. IFN-g ligation of its
receptor subunits (IFNGR-1 and -2) triggers recruitment of JAK
enzymes (JAK-1 and -2), which are transphosphorylated and, in
turn, phosphorylate the IFNGR (1) on tyrosines within the intra-
cellular domain that generate docking sites for STAT1. Recruited
STAT1 is phosphorylated by JAK2 and then homo- or hetero-
dimerizes and translocates into the cell nucleus where it binds to
specific promoters of IFN-g–dependent genes to induce their
transcription (12).
IgA is the predominant Ig at mucosal surfaces, and it can regu-
late myeloid leukocytes through the FcaRI (CD89). Thus, IgA is
mainly produced in mucosal tissues and is endowed with both
suppressive and activating effects [e.g., according to the level of
receptor cross-linking (13)] during the effector phase of inflam-
matory responses. Other properties include neutralization of
pathogens and poor proinflammatory capacity, such as for com-
plement activation. In contrast, it remains poorly known whether
IgA, abundantly present in subepithelial tissues and blood, can
also regulate the initiating steps of immune responses. We pre-
viously showed that IgA can induce IL-10 expression in human
monocytes (14) and monocyte-derived DCs (MD-DCs) (15). Be-
cause reciprocal inhibition may occur between autocrine IL-10
and IL-12 (16), the aim of the current study was to explore
whether IgA could also regulate IL-12 expression in human
monocytes and MD-DCs, as well as to investigate the molecular
mechanisms of this modulation, including the role of autocrine IL-
10 and intracellular signaling.
Materials and Methods
Study population
Peripheral blood was collected from volunteer donors. All donors were
healthy and exhibited no sign of active infectious or atopic disease. The
study was approved by the Ethics Committee of the Cliniques Universitaires
Saint-Luc, and all subjects gave written informed consent.
Isolation of monocytes and generation of DCs
Blood cells were layered over a Ficoll gradient (Lymphoprep; Axis-Shield,
Oslo, Norway). After centrifugation (800 3 g, 30 min), PBMCs were
isolated, washed, and resuspended in PBS ([pH 7.2] supplemented with
0.5% BSA and 2 mM EDTA). PBMCs were incubated with magnetic
beads conjugated with monoclonal mouse anti-human CD14 Abs (Miltenyi
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Biotec, Bergisch Gladbach, Germany) on ice for 15 min. After washing,
the cells were applied onto a column placed in the magnetic field of
a MACS separator (Miltenyi Biotec). After elimination of negative cells,
the column was removed from the separator, and the CD14+ cells
(monocytes) were collected and washed twice in RPMI 1640 (1:1; Lonza,
Verviers, Belgium) culture medium containing 10% heat-inactivated FCS,
2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (all
from Lonza).
For generation of myeloid DCs, monocytes purified by adherence were
treated according to the protocol described by Sallusto and Lanzavecchia
(17). Monocytes were differentiated into immature MD-DCs at 13 106/ml
in six-well flat-bottom culture plates in RPMI 1640 in the presence of GM-
CSF and IL-4 (both 20 ng/ml; R&D Systems, Oxfordshire, U.K.) for 6 d.
At the end of the culture, MD-DCs were harvested, washed, and used for
subsequent experiments.
Monocyte and MD-DC activation
Monocytes or MD-DCs (1 3 106 cells) were cultured in 12-well flat-
bottom plates in 1 ml (or alternatively for dose-response experiments,
2 3 105 cells in 96-well culture plates in 200 ml) RPMI 1640 culture
medium. Cells were incubated in triplicate at 37˚C, 5% CO2 for 24 h with
IFN-g (20 ng/ml; R&D Systems) in the presence or absence of dimeric IgA
(1 mg/ml), prepared from myeloma serum in our laboratory; unless oth-
erwise indicated, IgA treatment refers to this myeloma IgA. In addition,
normal monomeric IgA prepared from a pool of normal human serum was
used (at a concentration of 1 mg/ml). Culture was then carried out with
medium or with LPS (1 mg/ml; Sigma, St. Louis, MO) at 37˚C, 5% CO2
for another 24 h. The inhibitors or Abs were added 1 h (at 4˚C) before cell
stimulation; the concentration used was 50 mM for PD-98059, SB-203580
(Biomol International, Plymouth Meeting, PA), SP-600125 inhibitors
(A.G. Scientific, San Diego, CA), and AG-490 inhibitor (Sigma). Cross-
linking Ab to CD89 (clone MIP7c; Pierce, Rockford, IL) and control
mouse IgG (kind gift from Prof. J.P. Coutelier, de Duve Institute, Brussels,
Belgium) were used at 10 mg/ml. In selected experiments, monocytes were
preincubated at 4˚C on ice with IgA and F(ab9)2 fragments [prepared using
ImmunoPure F(ab9)2 preparation kit from Pierce of affinity-purified goat
ACP17 anti-human IgA, previously generated in our laboratory] separately
(twice for 30 min), with a gentle wash between incubation before IFN-g
priming and LPS stimulation. After 48 h, cells were harvested for phe-
notypic analysis by flow cytometry, optical microscopy (using a Axiovert-
40 microscope; Zeiss, Jena, Germany), or RT-PCR analyses, and super-
natants were collected and frozen (220˚C) until cytokine assays.
Flow cytometry
Monocyte and myeloid DC purity was assessed by FACS analysis using the
following surface markers: CD1a-FITC, HLA-DR-PerCP, CD80/B7.1-PE,
CD86/B7.2-PE, CD83-FITC, CD11c-allophycocyanin, and CD14-FITC
(all from BD Biosciences, San Diego, CA). CD89/FcaRI and CD64/
FcgRI (BD Biosciences) were also assessed before/after monocyte stim-
ulation (as a marker of IFN-g–induced monocyte activation). Immuno-
staining was carried out in PBS–2% FBS (Lonza) before washing and
fixation in 0.5% formaldehyde (Sigma). Acquisition was carried out for
monocytes on 10,000 CD14+-gated cells/condition, using a FACS Canto II
(BD Biosciences). Results are expressed as mean fluorescence intensity,
corrected for the isotypic control.
Cytokine assays
IL-12p40 and IL-12p70 were measured by sandwich ELISA in the cell
culture supernatants using paired Abs (R&D Systems), with a sensitivity
of 16 pg/ml for each assay. CXCL-10/IP-10 and CCL22/MDC were also
quantified by ELISA (R&D Systems).
Quantitative RT-PCR for p40, IL-12p35, and STAT1
Total RNAwas isolated using the RNeasy Plus Mini kit (QIAGEN, Hilden,
Germany). Total RNA was reverse transcribed with a RevertAid Reverse
Transcriptase kit (Fermentas, St. Leon-Rot, Germany) with 0.3 mg random
hexamer (Invitrogen, Carlsbad, CA) and 1 mM each deoxynucleotide tri-
phosphate (Invitrogen), following the manufacturer’s protocol, in a ther-
mocycler (Applied Biosystems, Carlsbad, CA). The expression levels were
quantified by real-time quantitative PCR with the iCycler IQ5 PCR (Bio-Rad,
Hercules, CA). The reaction mix contained 5 ml cDNA diluted 10-fold,
400 nM each primer (p40 reverse: 59-AACCTAACTGCAGGGCACAG-39;
p40 forward: 59-CGGTCATCTGCCGCAA-39; p35 reverse: 59-ATTCTA-
GAGTTTGTCTGGCCTT-39; p35 forward: 59-CACTCCAGACCCAG-
GAATGTT-39; STAT1 reverse: 59-GTGTTCTCTGTTCTGCAAGGTTT-39;
STAT1 forward: 59-TGAAGGACAAGGTTATGTGTATAGAGC-39; RPS18
reverse: 59-TGATCACACGTTCCACCTCAT-39; RPS18 forward: 59-
TGTGGGCCGAAGATATGCT-39), and 23 iQ SYBR Green SuperMix
(Bio-Rad) in a final volume of 20 ml. The cycling conditions were 95˚C for
FIGURE 1. Inhibition by IgA of
p40 and IL-12p70 production by
human monocytes primed by IFN-g
and stimulated by LPS. Dose re-
sponse of p40 (A, n = 3) and IL-
12p70 (B, n = 2) production upon
LPS stimulation following priming
with increasing concentrations of
IFN-g from 5 to 80 ng/ml. Effect of
IgA on monocyte production of p40
(C, n = 8) and IL-12p70 (D, n = 9)
after IFN-g and/or LPS stimulation.
(E and F) Effect of IgA on monocyte
expression of p40 mRNA and IL-
12p70 mRNA by RT-qPCR, cor-
rected for RPS18. Results depict
mean 6 SEM. **p , 0.01, ***p ,
0.001.
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3 min, followed by 40 cycles of 95˚C for 15 s and 60˚C for 30 s. A melting
curve analysis was performed to control the specificity of the amplification
products. Moreover, the negative controls (water and RT) showed no
amplification. Samples were run in duplicates, and the copy number was
calculated from a standard curve. The standard curve and data analysis
were produced using Bio-Rad iQ5 Software.
Western blot for p-MAPKs and STAT1
Monocytes were stimulated by IFN-g/LPS, with or without IgA, as de-
scribed above, in 12-well plates at 2 3 106 cells/well in duplicate. Cells
were subsequently lysed for 30 min on ice in 150 ml RIPA lysis buffer
(50 mM Tris-HCl [pH 7.4], 0.25% sodium deoxycholate, 150 mM NaCl,
1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF). Lysates were
clarified by centrifugation at 4˚C for 10 min at 10,000 3 g. Equal amounts
of lysates were separated by 12% SDS-PAGE and electrotransferred onto
a nitrocellulose membrane and subjected to immunoprobing using Abs to
phosphorylated or unphosphorylated MAPKs ERK1/2, p38-MAPK, JNK,
and STAT1 (1:1000, rabbit polyclonal Ab; Cell Signaling Technology, Danvers,
MA) or GAPDH (1:5000, rabbit polyclonal Ab; Sigma). Secondary Abs
consisted of HRP-conjugated goat IgG anti-rabbit IgG (1:2000; Cell Sig-
naling Technology). Immunoreactive bands were developed using chemi-
luminescence (Amersham ECL; GE Healthcare, Buckinghamshire, U.K.)
and detected with a Chemidoc XRS apparatus (Bio-Rad). The intensity of
each band was measured with the densitometry program Quantity One
(Bio-Rad).
Statistical analysis
Data are presented as mean 6 SEM, unless otherwise stated. Comparisons
were carried out using the two-tailed paired t test, with the Bonferroni
correction applied for multiple comparisons, with GraphPad Prism 4.0
(GraphPad Prism, San Diego, CA). The p values , 0.05 were considered
statistically significant.
Results
Inhibition of IL-12 production by IgA
A sharp priming effect of IFN-g was confirmed on p40 (Fig. 1A)
and IL-12p70 release (Fig. 1B) by LPS-activated monocytes. In
this system, highly significant reductions in IL-12 release by activated
monocytes were observed following pretreatment (concomitantly
with IFN-g) with IgA (Fig. 1C, 1D), particularly on IL-12p70.
Thus, although IgA exhibited a stimulating effect that was am-
plified by IFN-g, a striking inhibitory effect of IgA was observed
on IL-12p40 and p70 following combined IFN-g priming and LPS
stimulation (Fig. 1C, 1D). At the gene level, although marginal
changes in p40 mRNA were observed in IgA-treated monocytes
(Fig. 1E), IL-12p35 mRNAwas very significantly reduced by IgA
following IFN-g or IFN-g/LPS stimulation (Fig. 1F).
IgA-mediated suppression of the priming effect of IFN-g on
IL-12 production
To evaluate whether suppression by IgA involved interference with
LPS and/or IFN-g pathways, a washout experiment was carried
out. Monocytes were washed after IFN-g preincubation (with or
without IgA), before LPS stimulation (Fig. 2). In its absence
during LPS incubation (washout), IgA preincubation could not
prevent the effect of LPS, whereas IgA’s effect on IFN-g priming
was maintained (Fig. 2B versus 2A). These results suggested that,
to inhibit IL-12, IgA could target, at least in part, IFN-g signaling.
Inhibition by IgA of IFN-g–dependent signals
The Th1-related chemokine CXCL10 (IP-10) was assessed as
another IFN-g–dependent signal. CXCL10 was induced by IFN-g
stimulation, as well as by LPS to a much lower extent; both effects
were independently suppressed by preincubating cells with IgA
(Fig. 2C). In contrast, the Th2-related chemokine CCL22 (MDC)
was induced upon IgA treatment of monocytes to a greater extent
than with LPS (Fig. 2D).
Dose-response experiments showed that inhibition occurs at
IgA concentrations from 0.1 mg/ml and that IL-12p70 was more
FIGURE 2. Dose-response effect of IgA on
IFN-g priming for IL-12 and CXCL10/IP-10
production. Effect of IgA on monocyte pro-
duction of p40 without (A, n = 3) or after (B, n =
3) washout following IFN-g priming. Effect of
IgA on CXCL-10 (C, n = 8) and CCL22/MDC
(D, n = 6) production. (E) Inhibition percentage
of p40, IL-12p70, and CXCL10/IP-10 in IFN-
g–primed LPS-stimulated monocytes by various
concentrations of IgA (n = 2). (F) Effect of
different IgA concentrations on CCL22/MDC
release (n = 2). Results depict mean 6 SEM.
*p , 0.05, **p , 0.01, ***p , 0.001.
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sensitive to inhibition by IgA than was p40 or CXCL10 (Fig. 2E),
whereas upregulation of CCL22 required higher concentrations
($0.5 mg/ml) (Fig. 2F).
Inhibition of IL-12 and CXCL10 by different forms of human IgA
To exclude a particular effect of myeloma IgA, inhibition was
confirmed using IgA purified from a pool of normal human serum.
Monocytes were incubated with IFN-g and normal serum IgA
before LPS stimulation. Inhibition of IL-12 in monocytes primed
by IFN-g/LPS (Fig. 3A, 3B) was similar to that observed with
myeloma IgA (Fig. 1C, 1D). The suppression of IFN-g–induced
CXCL10/IP-10 was also confirmed with normal IgA (Fig. 3C), in
a dose-dependent manner (Fig. 3D).
IgA-mediated inhibition of IL-12 and CXCL10/IP-10 is
dependent on FcaRI ligation
Cross-linking of IgA receptors using IgA, followed by anti-IgA Ab,
reproduced the inhibitory effect of IgA on IL-12 and CXCL10/IP-10
in IFN-g–primed LPS-stimulated monocytes (Fig. 4A). FcaRI/CD89
was then assessed as the putative receptor mediating these effects of
IgA. FcaRI cross-linking recapitulated the suppressive effect of IgA
on IL-12p40, in contrast to the nonsignificant effect with control
mouse IgG (Fig. 4B). These results indicated that the effect of IgA
on IL-12 is dependent on the myeloid FcaRI/CD89 receptor.
IgA-mediated inhibition of type 1 monocyte activation
In these cultures, the morphological features of monocytes acti-
vated by LPS and/or IFN-g were affected by IgA treatment. Thus,
activation by LPS and IFN-g resulted in the formation of cell
clusters, an effect largely inhibited in the presence of IgA
(Fig. 5A). Effects of IgA on markers of cell activation were then
assessed by flow cytometry. The presence of FcaRI was first
confirmed on freshly purified monocytes, and it was upregulated
following culture in the presence of IgA (Fig. 5B). FcgRI/CD64
was induced upon IFN-g treatment of monocytes, and expression
of the Ag presentation–related surface molecules HLA-DR,
CD80, and CD86 was strongly upregulated upon combined stim-
ulation with LPS and IFN-g (Fig. 5C). Both IFN-g–induced CD64
and LPS/IFN-g–driven upregulation of HLA-DR, CD80, and CD86
were inhibited in the presence of IgA. These morphological and
phenotypic effects further indicated that IgA suppresses IFN-g–
driven monocyte activation.
Inhibition of IL-12 release by IgA in DCs
As expected, in MD-DCs, LPS stimulation was sufficient to
induce IL-12 production, including bioactive IL-12p70, show-
ing that DCs are much less dependent on a second signal to
produce this cytokine than are monocytes. IgA was also able
to inhibit IL-12 release by MD-DCs stimulated by LPS or IFN-
g/LPS (Fig. 6A, 6B).
IgA-mediated inhibition of IL-12 is independent from IL-10
To address the role of autocrine IL-10, which is induced by IgA
in monocytes (14) and DCs (15) and can inhibit IL-12 produc-
tion (16), DCs were pretreated with a blocking mAb to human
IL-10Rb. Blockade of the IL-10 pathway induced a slight in-
FIGURE 3. Inhibition by normal serum IgA of
p40, IL-12p70, and CXCL10/IP-10 production by
human monocytes primed by IFN-g and stimulated
by LPS. Effect of normal IgA on monocyte pro-
duction of p40 (A, n = 3), IL-12p70 (B, n = 3), and
CXCL10/IP-10 (C, n = 3) after IFN-g and/or LPS
stimulation. (D) Effect of different concentrations
of normal serum IgA on CXCL10/IP-10 production
by monocytes primed by IFN-g and stimulated by
LPS (n = 3). Results depict mean6 SEM. *p, 0.05.
FIGURE 4. Effect of IgA/FcaR cross-linking on
monocyte IL-12 production, following priming by
IFN-g and LPS stimulation. (A) Inhibition percent-
age of p40, IL-12p70, and CXCL10/IP-10 in IFN-g–
primed LPS-stimulated monocytes by various con-
centrations of IgA + F(ab9)2 anti-IgA fragments (n =
2). (B) Inhibition percentage of p40 by monocytes
after IFN-g priming and LPS stimulation, in the
presence of IgA or cross-linking anti-FcaRI/CD89
Ab, compared with control mouse IgG (data are
representative of two separate experiments).
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crease in p40 and IL-12p70 production by DCs (Fig. 6C, 6D), as
expected, according to reciprocal inhibition between IL-10 and
IL-12, whereas isotype control had no effect. However, IL-10Rb
blockade did not affect the inhibitory effect of IgA on IL-12
production by DCs (Fig. 6C, 6D) or fresh monocytes (data not
shown).
IgA-mediated inhibition of IL-12 is independent from MAPK
regulation
MAPKs were assessed as intracellular signals potentially targeted
by IgA to inhibit IL-12 production in monocytes/DC. First, the
requirement of ERK, p38, and JNK for IL-12 (p40, p70) production
was addressed using selective inhibitors of these pathways (Fig. 7A,
FIGURE 5. Effects of IgA on phenotypic markers of monocyte activation. (A) Morphological effect of IgA on monocyte appearance in culture following
IFN-g and/or LPS stimulation. Monocytes were assessed by inverted optical microscopy at the end of the culture with IgA, with/without activation by IFN-
g and/or LPS. Scale bars, 50 mm. (B) Expression of FcaRI (CD89) on monocytes at baseline or after incubation with IgA. (C) Regulation by IgA of
activation markers of monocytes (i.e., HLA-DR, FcgRI/CD64, CD80, and CD86). Data are representative of three independent experiments and are
expressed as mean fluorescence intensity (MFI), corrected for the isotype control.
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7B), which were confirmed to suppress the target MAPK without
inhibitory effect on the two others, as well as to inhibit the LPS-
induced production of TNF and IL-10 (data not shown). Although
MAPK inhibitors had differential effects on p40 and IL-12p70 in
IFN-g/LPS-activated monocytes (Fig. 7A, 7B), IgA had no in-
hibitory effect on LPS-induced p38 and JNK phosphorylation and
a very modest effect on ERK (Fig. 7C). Thus, IgA had no sig-
nificant effect on MAPKs that could underlie its inhibitory effect
on IL-12.
Inhibition of STAT1 activation by IgA
Because JAK/STAT molecules are critical to IFN-g activity (18),
a potential interference between FcaR and IFN-g pathways was
investigated at this signaling level. Using a selective JAK2/STAT1
inhibitor (AG-490), we first confirmed the requirement of this
pathway for IL-12 production in activated monocytes. JAK2/STAT1
blockade resulted in a failure of LPS alone and the IFN-g/LPS
combination to elicit IL-12p40 release (Fig. 8A).
A marked reduction in LPS-induced STAT1 phosphorylation
was observed in IFN-g–primed monocytes following IgA pre-
incubation (Fig. 8B). In addition, a mild, but consistent, reduction
in total STAT1 was also observed following IgA pretreatment
(Fig. 8B).
Moreover, inhibition of STAT1 phosphorylation was also ob-
served upon IgA treatment following short-term IFN-g stimulation
(Fig. 8C). This latter effect required preincubation with IgA for
24 h and was not observed when IgA was added only 1 h before
IFN-g (data not shown), and it also resulted in a decrease in total
STAT1 (Fig. 8C). Finally, a reduction in transcription of STAT1 by
IgAwas confirmed in LPS-activated monocytes by RT-quantitative
PCR (RT-qPCR) for STAT1 mRNA (Fig. 9).
Discussion
IL-12 is the major Th1-polarizing factor, produced upon TLR-
mediated activation of DCs, to elicit IFN-g responses following
cognate interactions with T cells. To our knowledge, the present
study shows for the first time that, in human monocytes and MD-
DCs, IgA suppresses IL-12 induction upon IFN-g and LPS stim-
ulation. Suppression involved interference with both LPS and
IFN-g pathways, as indicated in washout experiments and by
concomitant inhibitory effects of IgA on other IFN-g–dependent
signals, such as chemokine IP-10/CXCL10, CD64, and Ag pre-
sentation–associated molecules. IgA-mediated inhibition of IL-12
expression did not involve autocrine IL-10 or modulation of
MAPKs, but it involved interference, via the myeloid FcaRI/
CD89 receptor, with the activation of STAT1 as the critical in-
tracellular signal in LPS- and IFN-g–activated monocytes.
Inhibition of IL-12 was described previously with various
mediators, through various mechanisms. Vitamin D3 inhibits IL-
12 expression via inhibition of binding to NF-kB site (19).
Glucocorticosteroids also suppress LPS-induced IL-12p40 tran-
scription by inhibiting c-Jun (5), which signals through AP-1 and
NF-kB (5, 20). PGE2 (21) and catecholamines (activating the b2-
adrenoreceptor) (22) inhibit IL-12 production in human mono-
cytes through increased cAMP. In addition to these factors,
cross-linking of FcgR by IgG immune complexes renders murine
macrophages refractory to IL-12 production (23, 24), and recip-
rocal alteration in the production of IL-10 and IL-12 by IgG
immune complexes has been observed. It was shown that the
effect of IgG on IL-12p40 involves PI3K signaling and inhibition
of NF-kB binding (25). It was also described that murine mac-
rophages infected with the Ross River virus in the presence of
LPS and subneutralizing concentrations of IgG Abs display
reduced IFN-g and TNF-a responses, which correlated with
reduced STAT1 and NF-kB activation, respectively (26); how-
ever, this was not mediated through FcgR, because nonviral (zy-
mosan) immune complexes failed to suppress STAT1 and NF-
kB binding.
A strong inhibition of IL-12 expression was observed with IgA
on IL-12p70 at the protein and gene (p35) levels in LPS+IFN-g–
treated monocytes, whereas inhibition of p40 was observed to
a lower extent and mainly at the protein level. In addition, a mild
induction of IL-12p70 is observed with IgA in IFN-g–treated cells
in contrast to p35mRNA inhibition, further suggesting that IgA
operates through both transcriptional and posttranscriptional
mechanisms. In addition to IL-12 inhibition, we show that IgA is
able to inhibit CXCL10/IP-10, a major chemokine for Th1 cells.
Moreover, it can also concomitantly induce CCL22/MDC pro-
duction (a prototypical Th2 chemokine), further suggesting that
IgA could display pro-Th2 effects during developing immune
responses. Considering the activities of IL-4 and IL-5 as Th2
cytokines able to promote IgA transport and synthesis, respec-
FIGURE 6. Inhibition by IgA of p40 and IL-12p70
production by MD-DCs and role of autocrine IL-10.
Effect of IgA on MD-DC production of p40 (A, n = 4)
and IL-12p70 (B, n = 4) after IFN-g and/or LPS
stimulation. Effect of blocking IL-10Rb on IgA-
driven inhibition of p40 (C, n = 2) and IL-12p70 (D,
n = 2) following IFN-g/LPS stimulation. Results de-
pict mean 6 SEM. *p , 0.05.
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tively, a positive-feedback loop might operate between IgA reg-
ulation and Th2 mucosal immunity.
Our data show that IgA affects, through the regulation of myeloid
cells, Th1-type immunity and the activation of STAT1 following
LPS or IFN-g activation. STAT1 is typically induced by (type 1
and 2) IFNs (27), whereas it is also induced by IL-12 itself, de-
spite the fact that STAT4 represents the critical STAT for IL-12
signaling. Thus, this latter autocrine loop could underlie the ob-
served inhibitory effect of IgA on total STAT1 levels. LPS, which
directly triggers NF-kB activation, may induce STAT1 activation
that is mediated by type I IFNs (IFN-a/b). Control of JAK/STAT-
signaling pathway includes endogenous inhibitors [i.e., SOCS
proteins consisting of proteins with a central SH2 domain and a C-
terminal “SOCS” box (28)], which also regulate other cytokine
and hormone receptors, such as epidermal growth factor receptor
(29) and IL-10–driven inhibition of IFN-a– and IFN-g–dependent
genes (30). Therefore, it is tempting to speculate that IgA treat-
ment of monocytes and DCs interferes with IFN-g signaling by
recruiting endogenous inhibitors of STAT1.
Previous studies showed that ERK activation could mediate the
suppressive effect of Leishmania phosphoglycans (31) or Candida
albicans (32) on IL-12 expression, whereas this was not observed
following FcgR (13) or FcaR ligation (this study). In line with
previous studies in PBMCs (33) and monocytes/macrophages (5,
31), IL-12 production was independent of p38 MAPK activation
in human monocyte–derived cells stimulated by IFN-g and LPS;
rather, it depended on JNK. Conversely, p38 MAPK inhibition
upregulated p40 production in these studies, indicating a suppres-
sor role on IL-12, which was also reported for JNK in human
macrophages (34) and activated monocytes (35). Our data also
show upregulation of IL-12 p40 upon ERK or p38 inhibition,
whereas p38 or JNK targeting reduced the production IL-12p70.
Nevertheless, IgA had no significant effect on MAPK activation
that could underlie its inhibitory effect on IL-12.
FIGURE 7. Effect of IgA on MAPK activation following IFN-g priming and LPS stimulation. Effect of MAPK inhibitors (PD-98059, SB-203580, SP-
600125 for ERK1/2, p38, JNK MAPKs, respectively) on p40 (A, n = 3) and IL-12p70 (B, n = 3) production by monocytes stimulated by IFN-g and LPS,
with or without IgA. (C) Effect of IgA on phosphorylation of ERK1/2, p38, and JNK MAPKs following IFN-g priming (for 24 h) and LPS stimulation for
15, 30, or 60 min. Normalization was performed on the respective total (unphosphorylated) MAPKs and on GADPH, used as a loading control. Right
panels, Quantification of each p-MAPK corrected for total MAPK. Data are representative of two independent experiments.
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We previously showed that IgA may induce IL-10 expression in
monocytes and MD-DCs (15), and IL-10 may also control IL-12
expression in an autocrine manner (16, 36), as observed following
IgG ligation of FcgRs. However, autocrine IL-10 was not involved
in the IgA-mediated inhibition of IL-12. Rather, we show that
IL-12 suppression by IgA is recapitulated by FcaRI/CD89 cross-
linking and extends to other signatures of type 1 activation in
monocytes, such as cluster formation, release of CXCL10/IP10,
and upregulated FcgRI/CD64 and HLA-DR and costimulatory
(CD80, CD86) molecules upon IFN-g/LPS stimulation. Although
it remains to be explored whether IgA specifically regulates M1
versus M2 differentiation, these data suggest that IgA could inter-
fere with these proinflammatory pathways at the level of myeloid
cell activation and that this occurs by suppressing STAT1 signaling.
IgA-mediated immunoregulation of IFN-g responses may be
relevant to T cell–mediated inflammatory diseases, particularly
those associated with Th1-type immunopathology, such as sar-
coidosis, Crohn’s disease, multiple sclerosis, and experimental
FIGURE 8. Effect of IgA on STAT1
activation following IFN-g and/or LPS
stimulation. (A) Effect of JAK2/STAT1
inhibitor (AG-490) on monocyte pro-
duction of p40 following IFN-g and/or
LPS stimulation. Results depict mean 6
SEM from two independent experi-
ments. (B) Effect of IgA on STAT1
phosphorylation in monocytes primed
by IFN-g (for 24 h) and stimulated by
LPS for 15, 30, or 60 min. Controls
included IFN-g, IFN-g + IgA (for 24 h),
and LPS alone (for 15 min). Normali-
zation was performed on total (unphos-
phorylated) STAT1 and GAPDH. Lower
panels, Quantification of p-STAT1 and
total STAT1 corrected for GADPH. (C)
Effect of IgA on STAT1 phosphoryla-
tion in monocytes activated by IFN-g
for 15–120 min. Normalization was
performed on total (unphosphorylated)
STAT1 and GAPDH. Lower panels,
Quantification of p-STAT1 and total
STAT1 corrected for GADPH. Data are
representative of three independent
experiments. *p , 0.05, **p , 0.001.
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autoimmune encephalomyelitis. This might also be relevant to
asthma, for which a dual role for IL-12 was demonstrated in a
murine model (37). It was shown that, despite the fact that IL-12
counteracts Th2 responses during allergen sensitization, it can
enhance, on further allergen exposure, the recruitment of CD4+
T cells and granulocytes, as well as Th2 cytokines and chemo-
kines; this unexpected proallergic role of IL-12 was not observed
in IFN-g–deleted mice. Also, upregulated STAT1 phosphorylation
was detected in target tissue of inflammation in asthma (38), in-
flammatory bowel disease (39), and rheumatoid arthritis (40). In
addition, our data showing IgA-mediated suppression of IFN-g–
driven CD64 expression and surface molecules involved in Ag
presentation might suggest that IgA could represent a soluble factor
that limits local activation of freshly recruited monocytes at mu-
cosal tissue sites of ongoing inflammatory responses by suppressing
IFN-g–dependent activation of these proinflammatory pathways
engaged for Ag presentation to, and type 1 activation of, T cells.
Interestingly, it was reported that selective IgA deficiency is
associated with some Th1 diseases, such as Crohn’s disease (41),
and with upregulated IL-12 production (42), although the latter
could not be localized to monocytes. It also remains possible that
the association between autoimmunity and IgA deficiency relates
to a common genetic susceptibility (43).
In conclusion, IL-12 plays essential roles in protective cellular
immunity to intracellular pathogens by directing the development
of Th1 cells, whereas uncontrolled inflammatory reactions may
underlie several inflammatory diseases. We believe that the IgA/
FcaRI-mediated regulatory pathway, identified in this in vitro
study, may contribute to fine tuning of immune activation and
prevention of Th1-mediated mucosal immunopathology by sup-
pressing IFN-g priming and STAT1 activation and, thereby, type 1
imprinting of monocytes and DCs. It remains to be investigated
whether IgA is also able to turn off type 1 immune activation in
vivo. This novel IgA pathway could participate to downregulate
the immune potential to induce proinflammatory responses, par-
ticularly at mucosal surfaces that are continuously exposed to
commensal and pathogenic microorganisms and Ags and where
IgA is predominantly produced.
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